clinical trial · NCT05243524
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)·phase2·terminated·n = 16
Platinum-resistant Epithelial Ovarian CancerMaveropepimut-SCyclophosphamide 50mg
brief summary
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
started
Aug 5, 2022
primary completion
Jul 24, 2023
completion
Aug 31, 2023
last updated
Sep 13, 2023
detailed description
A Simon two-stage statistical design to assess MVP-S in combination with low dose CPA in platinum-resistant epithelial ovarian cancer patients who have received no greater than 4 previous lines of anti-cancer therapy.
MVP-S, previously called DPX-Survivac, was recently evaluated in a small Phase 2 single arm study of ovarian cancer patients known as DeCidE1 (NCT02785250).
official title
Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol